Akt, a proto-oncogene that encodes a cytosolic serine/ threonine kinase, can phosphorylate and modulate the activity of several proteins involved in cellular metabolism and survival. Recently, two mammalian highly related forkhead transcription factors FKHRL1 and AFX and their nematode homologue Daf-16 have been found to be targets of this kinase. Here we show that Akt, but not inactive Akt, represses the transcriptional activity of FKHR, another member of the forkhead family. FKHR mutants with alanine substitutions at three Akt phosphorylation consensus sites (T24, S256 and S319) were inhibited by Akt, but mutation of all three sites rendered FKHR resistant to suppression. By contrast, the transcriptional activity of the oncogenic PAX3 ± FKHR fusion protein, containing two consensus phosphorylation sites, was not inhibited by Akt. Importantly, Akt inhibited the translocation of FKHR to the nucleus, providing a mechanism by which Akt might regulate the transcriptional activity of FKHR. Consistent with this model, the localization of the PAX3 ± FKHR fusion protein was nuclear and was not altered by Akt. These results provide evidence that Akt inhibits the transcriptional activity of FKHR by controlling its tracking into the nucleus and that oncogenic PAX3 ± FKHR can escape this negative regulation by Akt.
Introduction
The gene encoding the serine/threonine kinase Akt/ PKB was ®rst identi®ed as an oncogene in acute transforming retroviruses (Bellacosa et al. 1991) . Its cellular counterpart has been found to be activated by the lipid products of the phosphatidylinositol 3-kinase (PI3K) (Franke et al., 1995) that are generated upon transduction of signals emerging from dierent membrane receptors. The PI3K/Akt pathway has been implicated in transduction of signals aecting cellular growth, survival and metabolism (Coer et al., 1998) . Several proteins have been identi®ed in mammalian cells that are direct targets of Akt and appear to account for some of the biological activities of the PI3K/Akt pathway, including the glycogen synthase 3-kinase (Cross et al., 1995) , the pro-apoptotic Bcl-2 family member BAD (Datta et al., 1997; del Peso et al., 1997) , and caspase-9 (Cardone et al., 1998) . Genetic analyses in the nematode Caenorhabditis elegans have shown that in the worm the PI3K/Akt pathway culminates in the regulation of the forkhead transcription factor Daf-16 (Lin et al., 1997; Ogg et al., 1997; Paradis and Ruvkun, 1998) . Recent studies have shown that the mammalian forkhead transcription factors FKHRL1 (Brunet et al., 1999) and AFX (Kops et al., 1999) are direct targets of Akt. These studies have suggested that the transcriptional activity of FKHRL1 and AFX is negatively regulated by phosphorylation at three dierent residues by Akt (Brunet et al., 1999; Kops et al., 1999) .
In the present study, we have investigated the regulation of a third member of the forkhead transcription factor family, FKHR, by Akt. FKHR is closely related to the mammalian AFX and FKHRL1, as well as to the nematode DAF-16 proteins. In addition to being involved in transcription of target genes, FKHR has been implicated in oncogenesis as a result of its involvement in the chromosomal translocation t(2;13)(q35;q14) frequently found in human alveolar Rhabdomyosarcomas Galili et al., 1993; Shapiro et al., 1993) . This translocation leads to the generation of a chimeric gene composed of PAX3, a member of the paired box transcription factor family, and FKHR Galili et al., 1993; Shapiro et al., 1993) . The resulting PAX3 ± FKHR fusion protein contains an intact DNA-binding domain of PAX3 fused to the COOH-terminal half of the fork head domain and the transactivation domain of FKHR Galili et al., 1993; Shapiro et al., 1993) . Signi®cantly, the PAX3 ± FKHR product exhibits potent transactivation activity when compared to wild-type PAX-3 (Bennicelli et al., , 1996 Fredericks et al., 1995; Sublett et al., 1995; Lam et al., 1999) . Importantly, two of the three putative phosphorylation Akt sites on FKHR are retained in the PAX3 ± FKHR fusion protein raising the possibility that the transcriptional activity of this oncogenic protein might be regulated by Akt.
Results

FKHR transcriptional activity is regulated by Akt
Forkhead transcription factors regulate gene expression by binding to consensus binding sites in promoter *Correspondence: G NuÂ n Ä ezregions (Pierrou et al., 1994) . It has been reported that the insulin-like growth factor-binding protein (IGFBP-1) gene promoter is regulated by the PI3K/Akt pathway (Cichy et al., 1998) . Signi®cantly, the DNA sequence in the IGHBP-1 promoter that is regulated by this pathway, the insulin-responsive sequence (IRS), matched the consensus sequence recognized by nematode Daf-16 (Paradis and Ruvkun, 1998) , suggesting that mammalian forkhead proteins may recognize the same promoter element. To test this, we generated a reporter construct containing an IRS from the IGFP-1 promoter linked to a ®re¯y luciferase reporter gene and assessed the regulation of FKHR activity by Akt. As shown in Figure 1b , expression of FKHR induced transcription of the reporter IGFBP-1 promoter construct and this activity was inhibited in a dose-dependent manner by Akt (Figure 1b) . Analysis of the FKHR sequence revealed three sites that conform to the consensus site (RXRXXS/T) phosphorylated by Akt (Alessi et al., 1996) . The three Akt consensus sites were located at T24, S256 and S319, and were conserved in FKHRL1 and AFX (Figure 1a ). These consensus sites in FKHRL1 and AFX have been recently shown to be phosphorylated by Akt (Brunet et al., 1999; Kops et al., 1999) . In order to demonstrate that the inhibition of FKHR activity by Akt was dependent on these sites, we generated mutants (FKHRm1P, FKHRm2P and FKHRm3P) in which T24, S256 or S319 respectively were replaced by alanine residues. Mutation of each individual site had little, if any, eect on Akt-mediated inhibition of FKHR activity when compared to wild-type FKHR (Figure 1c ). However, mutation of all three sites (mutant FKHRm123P) rendered FKHR insensitive to Akt inhibition ( Figure 1c) . Importantly, inhibition of FKHR transactivation activity by Akt required an intact kinase activity because expression of a kinase defective mutant in which the lysine of the adenosine triphosphate (ATP)-binding site was replaced by a methionine did not inhibit the transcriptional activity 
The transcriptional activity of PAX3 ± FKHR fusion protein is not regulated by Akt
Since the human oncogenic PAX3 ± FKHR chimeric protein retains two of the Akt-phosphorylation sites (Figure 2a ) and the presence of these two sites (S256 and S319) are sucient for Akt to inhibit FKHR activity (see mutant FKHRm1P in Figure 1c) , we examined whether Akt could regulate the transcriptional activity of the chimeric PAX3 ± FKHR protein.
In addition, we constructed a PAX3 ± FKHR mutant form (PAX3-FKHR m23P) in which the two consensus phosphorylation sites were replaced by alanine residues. As shown in Figure 2b , expression of Akt potently inhibited the transcriptional activity of FKHR. In contrast, Akt had a minor eect on the transcriptional activity of FKHRm123P, PAX3 ± FKHR or PAX3 ± FKHRm23P that was only observed at high doses of Akt (Figure 2b ).
Akt controls FKHR, but not PAX3 ± FKHR, subcellular localization
Regulation of transcription factors by phosphorylation may involve dierent mechanisms including alteration in DNA binding, activation or inhibition of the transactivation domain, or regulation of their subcellular localization. We asked next whether Akt might regulate the transcriptional activity of FKHR by controlling the subcellular localization of this transcription factor. To test this possibility, we transfected HEK293T cells with plasmids producing FKHR, PAX3 ± FKHR or mutant forms in which the consensus Akt phosphorylation sites have been replaced by alanine residues. After transfection, cells were serum starved and treated with LY294002, an inhibitor of PI3K, to prevent activation of the endogenous PI3K/Akt signaling pathway. The subcellular localization of each protein was determined by immunostaining and visualized by laser confocal microscopy. Under quiescent conditions, wild-type FKHR was localized in the cytoplasm, nucleus or in both nuclear and cytoplasmic compartments (Figures 3 and 4) . Coexpression of a constitutively active form of Akt under the same conditions resulted in increased localization of FKHR in the cytoplasm with few cells, if any, showing an exclusively nuclear distribution (Figures 3 and 4) . In contrast to wild-type FKHR, a form of FKHR in which all three consensus Akt phosphorylation sites have been mutated to alanine, localized in the nucleus and the presence of active Akt had little eect on its localization (Figures 3 and 4) . The PAX3 ± FKHR fusion protein exhibited a nuclear localization and this distribution was not altered by Akt (Figures 3 and 4) . In contrast, the localization of mutant FKHRm1p, containing the same consensus Akt phosphorylation sites as PAX3 ± FKHR, was cytoplasmic or both cytoplasmic and nuclear with less than 15% of the cells showing an exclusively nuclear distribution ( Figure 4b ). As it was observed with wild-type FKHR, the nuclear distribution of the FKHRm1p mutant was inhibited by Akt (Figure 4b) , consistent with the ability of Akt to suppress the transcriptional activity of this mutant ( Figure 1c ). As expected, the localization of a mutant form of PAX3 ± FKHR in which the consensus Akt phosphorylation sites have been replaced by alanine residues (PAX3 ± FKHRm23P) was nuclear and was not aected by Akt (Figure 4b ). 
Discussion
These results suggest that Akt regulates the transcriptional activity of FKHR by inhibiting its nuclear translocation and thereby repressing its ability to bind nuclear partners and target DNA sequences. This mechanism is consistent with genetic analysis in C. elegans that showed that Akt acts to antagonize the function of the FKHR homologue DAF16 in the worm (Paradis and Ruvkun, 1998) . Similarly, recent studies have suggested that Akt inhibits the activity of FKHRL1, another forkhead transcriptional factor, by regulating its nuclear translocation (Brunet et al., 1999) . Taken together, these results suggest an evolutionarily conserved mechanism by which the PI3K/Akt signaling pathway controls forkhead transcriptional factors and gene expression. In contrast to the potent inhibitory eect of Akt on the transcriptional activity of wild-type FKHR, the mutant FKHRm123P was mostly refractory to this inhibition. However, we have consistently found that, at high doses of Akt, the transcriptional activity of FKHRm123P (as well as that of PAX3 ± FKHR and PAX3 ± FKHRm23P) are modestly aected. The small inhibitory eect on the latter proteins appears non speci®c in that Akt, at high doses, also caused slight inhibition of the basal transcription of the reporter luciferase plasmid and that of a control NF-kB reporter construct (L del Peso and G NuÂ nÄ ez unpublished). However we can not rule out the possibility that another kinase(s), acting downstream of Akt, regulates these proteins.
The oncogenic PAX3 ± FKHR contains two consensus Akt phosphorylation sites but was not regulated by Akt. In contrast, the transcriptional activity of mutant FKHRm1P containing the same Akt phosphorylation sites as PAX3 ± FKHR was inhibited by Akt. This result might be explained by the observation that the subcellular localization of PAX3 ± FKHR is constitutively nuclear whereas FKHRm1P is retained in the cytoplasm. These results suggest that PAX3 sequences within PAX3 ± FKHR are dominant over FKHR regulatory sequences. In this model, sequence within PAX3 controls the nuclear localization of the chimeric PAX3 ± FKHR protein. Alternatively, the FKHR portion of PAX3 ± FKHR may adopt a conformation that is not amenable to Akt phosphorylation and regulation. PAX3 ± FKHR is oncogenic and its transforming activity depends on the PAX3 homeodomain recognition helix and the FKHR transactivation domain (Lam et al., 1999) . Because the transcriptional activity of PAX3 ± FKHR is not inhibited by Akt, oncogenic PAX3 ± FKHR would be unopposed in cancer cells that may require active Akt for survival and proliferation. Our results are in agreement with a recent study showing that stimulation of the insulin-like growth factor receptor (IGF-R), a potent activator of the P13K/Akt pathway, cooperates with PAX3 ± FKHR for transformation (Wang et al. 1998) .
Akt has been involved in several biological functions, including the transduction of survival signals. Interestingly, it has been shown that FKHRL1 can induce apoptosis by up-regulation of proteins involved in death receptor signaling and that Akt antagonizes this eect by inhibiting its transcriptional activity (Brunet et al. 1999) . Under our experimental conditions, transfection of FKHR, FKHRm123P, PAX3-FKHR or PAX3-FKHRm23P into HEK293T or NIH3T3 cells did not induce apoptosis, whereas transfection of controls such as caspase-9 strongly induced apoptosis (L del Peso and G Nu Â nÄ ez, unpublished). This may indicate that FKHR and FKHRL1 have dierent target genes, a possibility that will be investigated in the future.
Materials and methods
Plasmid constructions
The FKHR reporter plasmid was constructed by cloning an IRS sequence (CAAAACAAACTTATTTTG) from the IGFBP-1 gene promoter (Cichy et al., 1998) into pGL2-promoter-Luciferase (Promega). The PAX3/PAX3-FKHR luciferase reporter construct was generated by subcloning the 6xPRS response element and E1b promoter (Bennicelli et al. 1996) into pGL2-basic-Luciferase (Promega). The expression plasmids producing N-terminal epitope-tagged FKHR and PAX3 ± FKHR and their mutant forms were generated by a polymerase chain reaction protocol and subsequent subcloning into a pcDNA3 plasmid (Invitrogene) engineered to code for a Flag-tag sequence. Authenticity of each construct was con®rmed by dideoxy sequencing.
Luciferase assay
NIH3T3 cells were seeded in 12-well plates at a density of 5610 4 cells/well. Cells were transfected with 0.5 mg of the indicated reporter plasmid (see Figure legends) together with 100 ng of renilla luciferase, pRLTK, plasmid (normalization plasmid, Promega) and the indicated amounts of transcription factors and Akt (see Figure legends) . Twenty-four hours after transfection, cells were harvested and ®re¯y and renilla luciferase activities were determined using a dual luciferase system (Promega). Fire¯y luciferase activity was normalized based on the renilla luciferase activity.
Immunoblotting
Cell extracts from the reporter assays were used to determine expression of transfected proteins. Equal amounts of renilla luciferase activity of each sample were loaded to normalize for dierent transfection eciencies. Cell extracts were resolved by SDS ± PAGE, proteins transferred to nitrocellulose membranes and detected with the indicated antibodies. Proteins were detected using a chemiluminescence method (Amersham).
Cell immunostaining and confocal microscopy
HEK293 cells were cultured on poly-L-lysine-coated cover slides and transfected with the indicated plasmids (see Figure legends) by the calcium phosphate method. After 24 h, cells were ®xed with cold methanol for 20 min at 7208C. To prevent non-speci®c hybridization, ®xed cells were blocked with 30% goat serum, 1% BSA in PBS. Cells were stained with 3 mg/ml of anti-Flag M2 monoclonal antibody (Sigma) and 0.3 mg/ml of rabbit anti-HA polyclonal serum (Y-11, Santa Cruz). Primary antibodies were labeled by incubation with FITCconjugated goat anti-mouse (Sigma) and Rhodamineconjugated goat anti-rabbit (Molecular Probes). Subcellular localization of proteins was assessed by laser-confocal microscopy (Biorad).
